Compare Stocks: NEUP, GANX, GUTS, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.71 -0.6%	$1.83	$1.53 ▼ $4.34	$74.63M	0.19	426,727 shs	383,504 shs
GUTS Fractyl Health	$0.41 -9.7%	$0.65	$0.38 ▼ $2.45	$64.72M	2.42	1.67 million shs	2.97 million shs
IBIO iBio	$1.13 +1.4%	$1.33	$0.78 ▼ $3.82	$72.35M	1.26	497,827 shs	531,249 shs
NEUP Neuphoria Therapeutics	$3.47 -1.1%	$3.78	$3.19 ▼ $21.40	$18.78M	0.75	15,629 shs	12,581 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	0.00%	-3.93%	-6.04%	-10.47%	-6.04%
GUTS Fractyl Health	0.00%	-16.27%	-40.84%	-46.64%	-72.34%
IBIO iBio	0.00%	-5.46%	-13.46%	-33.04%	+112,499,900.00%
NEUP Neuphoria Therapeutics	0.00%	-4.67%	-7.71%	+2.66%	-74.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.71 -0.6%	$1.83	$1.53 ▼ $4.34	$74.63M	0.19	426,727 shs	383,504 shs
GUTS Fractyl Health	$0.41 -9.7%	$0.65	$0.38 ▼ $2.45	$64.72M	2.42	1.67 million shs	2.97 million shs
IBIO iBio	$1.13 +1.4%	$1.33	$0.78 ▼ $3.82	$72.35M	1.26	497,827 shs	531,249 shs
NEUP Neuphoria Therapeutics	$3.47 -1.1%	$3.78	$3.19 ▼ $21.40	$18.78M	0.75	15,629 shs	12,581 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	0.00%	-3.93%	-6.04%	-10.47%	-6.04%
GUTS Fractyl Health	0.00%	-16.27%	-40.84%	-46.64%	-72.34%
IBIO iBio	0.00%	-5.46%	-13.46%	-33.04%	+112,499,900.00%
NEUP Neuphoria Therapeutics	0.00%	-4.67%	-7.71%	+2.66%	-74.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	338.60% Upside
GUTS Fractyl Health	2.40	Hold	$5.50	1,252.68% Upside
IBIO iBio	3.11	Buy	$5.29	369.84% Upside
NEUP Neuphoria Therapeutics	1.67	Reduce	$7.00	101.73% Upside

Current Analyst Ratings Breakdown

Latest NEUP, GANX, GUTS, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/4/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/27/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/20/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
8/6/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/6/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	$50K	1,492.49	N/A	N/A	$0.48 per share	3.56
GUTS Fractyl Health	$90K	719.14	N/A	N/A	$0.07 per share	5.81
IBIO iBio	$100K	723.49	N/A	N/A	$1.54 per share	0.73
NEUP Neuphoria Therapeutics	$1.17M	16.05	N/A	N/A	$4.55 per share	0.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$20.16M	-$0.50	N/A	N/A	N/A	N/A	-161.59%	-118.36%	11/11/2026 (Estimated)
GUTS Fractyl Health	-$140.95M	-$0.88	N/A	N/A	N/A	N/A	-1,362.10%	-84.89%	11/11/2026 (Estimated)
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	11/11/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$13.45M	-$6.22	N/A	N/A	N/A	N/A	-38.31%	-28.92%	10/5/2026 (Estimated)

Latest NEUP, GANX, GUTS, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/5/2026	Q4 2026	NEUP Neuphoria Therapeutics	-$1.58	N/A	N/A	N/A	N/A	N/A
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.07	$0.08 million	N/A
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A
8/10/2026	Q2 2026	GUTS Fractyl Health	-$0.1350	-$0.12	+$0.0150	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.02	4.36	4.36
GUTS Fractyl Health	1.41	3.15	3.15
IBIO iBio	N/A	7.85	7.85
NEUP Neuphoria Therapeutics	N/A	27.83	27.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%
GUTS Fractyl Health	N/A
IBIO iBio	7.90%
NEUP Neuphoria Therapeutics	15.90%

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	4.15%
GUTS Fractyl Health	8.36%
IBIO iBio	1.55%
NEUP Neuphoria Therapeutics	1.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	21	43.64 million	41.83 million	Optionable
GUTS Fractyl Health	73	159.18 million	145.87 million	N/A
IBIO iBio	23	64.31 million	63.31 million	N/A
NEUP Neuphoria Therapeutics	8	5.41 million	5.33 million	N/A

NEUP, GANX, GUTS, and IBIO Headlines

Recent News About These Companies

Contrasting Neuphoria Therapeutics (NASDAQ:NEUP) & Legend Biotech (NASDAQ:LEGN)

September 30, 2026 | americanbankingnews.com

Neuphoria Therapeutics (NEUP) Set to Post Earnings on Monday

September 28, 2026 | americanbankingnews.com

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Falls 61.8%

September 27, 2026 | americanbankingnews.com

Neuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026

September 19, 2026 | marketscreener.comM

Neuphoria Therapeutics Inc Ordinary Shares NEUP

August 14, 2026 | morningstar.comM

Neuphoria Therapeutics Inc (NEUP)

August 8, 2026 | investing.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

July 30, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

July 28, 2026 | globenewswire.com

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

July 24, 2026 | businesswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

July 24, 2026 | prnewswire.com

Small cap movers: Scancell heads to Nasdaq as AIM's headcount falls to 612

July 24, 2026 | msn.com

Scancell to go public after winning reverse merger bid for troubled Neuphoria

July 24, 2026 | fiercebiotech.comF

Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing

July 24, 2026 | uk.finance.yahoo.com

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

July 23, 2026 | globenewswire.com

Neuphoria Therapeutics Stock Dividends | NASDAQ:NEUP | Benzinga

July 11, 2026 | benzinga.com

Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes

July 3, 2026 | biospace.comB

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

July 1, 2026 | fiercebiotech.comF

MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership

July 1, 2026 | msn.com

Neuphoria Therapeutics Inc. Common Stock

June 27, 2026 | fxempire.comF

Neuphoria Therapeutics in Talks to Be Acquired by Scancell Holdings

June 27, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP, GANX, GUTS, and IBIO Company Descriptions

Gain Therapeutics NASDAQ:GANX

$1.71 -0.01 (-0.58%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.75 +0.04 (+2.11%)

As of 10/2/2026 07:59 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Fractyl Health NASDAQ:GUTS

$0.41 -0.04 (-9.66%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.42 +0.01 (+3.30%)

As of 10/2/2026 07:47 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

iBio NASDAQ:IBIO

$1.12 +0.02 (+1.35%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-2.22%)

As of 10/2/2026 07:55 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Neuphoria Therapeutics NASDAQ:NEUP

$3.47 -0.04 (-1.14%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$3.46 -0.01 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NEUP, GANX, GUTS, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NEUP, GANX, GUTS, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NEUP, GANX, GUTS, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP, GANX, GUTS, and IBIO Company Descriptions

Gain Therapeutics NASDAQ:GANX

Fractyl Health NASDAQ:GUTS

iBio NASDAQ:IBIO

Neuphoria Therapeutics NASDAQ:NEUP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NEUP, GANX, GUTS, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NEUP, GANX, GUTS, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NEUP, GANX, GUTS, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP, GANX, GUTS, and IBIO Company Descriptions

Gain Therapeutics NASDAQ:GANX

Fractyl Health NASDAQ:GUTS

iBio NASDAQ:IBIO

Neuphoria Therapeutics NASDAQ:NEUP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools